1. Home
  2. WVE vs APOG Comparison

WVE vs APOG Comparison

Compare WVE & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • APOG
  • Stock Information
  • Founded
  • WVE 2012
  • APOG 1949
  • Country
  • WVE Singapore
  • APOG United States
  • Employees
  • WVE N/A
  • APOG N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • APOG Auto Parts:O.E.M.
  • Sector
  • WVE Health Care
  • APOG Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • APOG Nasdaq
  • Market Cap
  • WVE 915.6M
  • APOG 818.5M
  • IPO Year
  • WVE 2015
  • APOG N/A
  • Fundamental
  • Price
  • WVE $6.95
  • APOG $43.27
  • Analyst Decision
  • WVE Strong Buy
  • APOG Hold
  • Analyst Count
  • WVE 13
  • APOG 1
  • Target Price
  • WVE $20.15
  • APOG $45.00
  • AVG Volume (30 Days)
  • WVE 1.0M
  • APOG 342.2K
  • Earning Date
  • WVE 08-07-2025
  • APOG 06-27-2025
  • Dividend Yield
  • WVE N/A
  • APOG 2.40%
  • EPS Growth
  • WVE N/A
  • APOG N/A
  • EPS
  • WVE N/A
  • APOG 2.36
  • Revenue
  • WVE $104,939,000.00
  • APOG $1,376,100,000.00
  • Revenue This Year
  • WVE N/A
  • APOG $4.04
  • Revenue Next Year
  • WVE $1.94
  • APOG N/A
  • P/E Ratio
  • WVE N/A
  • APOG $18.32
  • Revenue Growth
  • WVE N/A
  • APOG N/A
  • 52 Week Low
  • WVE $5.04
  • APOG $37.53
  • 52 Week High
  • WVE $16.74
  • APOG $87.93
  • Technical
  • Relative Strength Index (RSI)
  • WVE 53.71
  • APOG 64.03
  • Support Level
  • WVE $6.25
  • APOG $38.16
  • Resistance Level
  • WVE $7.10
  • APOG $49.99
  • Average True Range (ATR)
  • WVE 0.39
  • APOG 1.91
  • MACD
  • WVE -0.01
  • APOG 0.58
  • Stochastic Oscillator
  • WVE 75.27
  • APOG 46.07

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.

Share on Social Networks: